





#### **Disclaimer**



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

# **Speakers Today**



Ricardo Naranjo Fernandez CEO





Jossue Yesquen Lihim IRO




#### **Key Developments 1Q 2025**














- Debt restructuring remains a top priority for 2025. We continued to reduce our Net Debt/EBITDA ratio, reaching the **lowest level in the past five years.** We prioritized short-term debt repayments.
- In the first quarter of 2025, Camposol achieved an EBITDA of USD 55.4 million, a solid result for a first quarter, driven by strong agricultural strategies and an exceptional commercial and fruit allocation approach.



- Our strategic decision to further develop markets and extend our blueberry production window allowed us to increase volumes commercialized during the quarter, resulting in a higher contribution margin in this segment compared to last year.
- Additionally, we had a highly successful grape season, a trend that began in late 2024 and continued throughout the first quarter of 2025.
- The mango segment also performed well, returning to historical levels of profitability. While 2024 benefited from extraordinary pricing conditions due to limited market supply a context we capitalized on this year reflected normalized market dynamics with solid returns.




## Operational overview preliminary 1Q 2025 - Key metrics



#### Volume Sold (MT)






Volume sold in 1Q 2025 increased by 51% compared to 1Q 2024, primarily due to higher volumes of blueberry, mangoes, and grape.

#### Revenue USD (MM)






Revenue in 1Q 2025 was 18% higher than in 1Q 2024, driven by increased sales of blueberries and grapes.

#### **EBITDA USD (MM)**






EBITDA for the first quarter of 2025 reached USD 55.4 million, representing an 8.3% decrease compared to the same period in 2024. However, it is worth noting that this figure is double the EBITDA reported in the first quarter of 2023.

#### Net Income USD (MM)






Net profit for the first quarter of 2025 was USD 24.5 million, down 32% compared to the same period in 2024, but already higher than the total net profit recorded for the full year 2023.


### Operational overview preliminary 1Q 2025 - Crop performance






### Operational overview YTD 1Q 2025 - Crop performance LTM











2024





**Planted Hectares** 


2,729 o Peru:

Own Var: 64

o Total: 2,715








LTM 1Q 25


o Peru: 562











o Peru: 2,689


Colombia 2,058

Total has: 4,747










1,006 Peru:


Chile: 149

Total has: 2,024



### Operational overview preliminary 1Q 2025 - EBITDA reconciliation





Blueberry: Strategic pruning concentrated more volume in 1Q25, reinforcing year-round supply model, opening new markets, improving efficiency, and increasing gross margin to 44.5% (vs. 40.5% in 1Q24).


Mango: Strong 33% gross profit margin despite normalized pricing, confirming solid execution and profitability.

Other: Grapes: Strong quarter with 33% higher prices, 27% gross margin, and 24% lower costs thanks to better yields and improved crop management.

Selling expenses: The increase was mostly due to higher international shipping costs, as we moved larger volumes of fruit this quarter.

### Operational overview preliminary 1Q 2025 - Cash flow





Strong cash collections in 1Q 2025 from 2024-2025 blueberry campaign supported timely supplier payments.

Debt: USD 28M short-term debt reduction in 1Q 2025 using blueberry campaign collections, easing near-term cash pressure.

Capex focused on short-term growth and risk mitigation, plus new lab and nursery to scale our proprietary genetics and replanting program.




## Operational overview preliminary 1Q 2025 - Leverage and Debt profile



#### **Debt Profile**


We continued reducing total debt, with a notable decrease in short-term obligations. At the same time, we maintained a strong cash position of USD 33.4 million. Combined with committed credit lines, this comfortably covers all short-term maturities, placing us in a solid financial position for the upcoming quarters.



#### Total financing credit lines vs short term debt

☐ Total available credit line ☐ Working capital short term debt

Total available credit line / WKSTD



Strong liquidity support: Available credit lines represent ~6x our working capital debt. We continue to strengthen our solid relationships with financial institutions.


### Operational overview preliminary 1Q 2025 - Leverage and Debt profile




#### **Debt history**

Improved debt structure: Short-term debt now represents less than 10% of total debt, reflecting two years of disciplined deleveraging.

☐ Leases☐ Working capital lines☐ Loans & Bond



#### **Net Debt / EBITDA**



Net debt-to-EBITDA at 2.30x, the lowest level in five years — reflecting the positive impact of our strategy and consistent financial discipline.



## Financial Statements 1Q 2025 - Preliminary Income Statement



	For the period ended	
	31.03.2025	31.03.2024
Revenue	179,499	152,039
Cost of sales	(107,697)	(85,363)
Gross profit before adjustment for biological assets	71,802	66,676
Net adjust. from change in fair value of bio. Assets	1,452	-
Profit after adjustment from biological assets	73,254	66,676
Selling expenses	(24,109)	(13,905)
Administrative expenses	(5,587)	(5,576)
Other expenses	(1,803)	(975)
Otherincome	647	1,444
Net foreign exchange transactions gains (losses)	(886)	(1,956)
Operating profit	41,516	45,708
Share of gain (loss) of associated companies	544	-
Finance income	25	3,428
Finance costs	(9,323)	(11,032)
Profit (loss) before income tax	32,762	38,104
Income tax	(7,795)	(6,043)
Deferred income tax	(474)	3,921
Profit (loss) for the period	24,493	35,982

# Financial Statements 1Q 2025 - Preliminary Cash Flow



	For the period ended	
	31.03.2025	31.12.2024
Cash flow from operating activities		
Collections	186,266	569,302
Payment to suppliers and employees	(124,222)	(388,020)
Interest paid	(13,347)	(42,144)
Income tax paid	(6,479)	(6,419)
Custom duties refund collections	297	3,088
Other collections / payments	526	2,308
Other payments	(496)	(2,321)
Net cash (used in) provided by operating activities	42,545	135,794
Cash flow from investing activities		
Purchases of property, plant and equipment	(2,525)	(9,318)
Investment in biological assets	(7,510)	(21,468)
Purchases of intangibles, excluding goodwill	(146)	(730)
Acquisition of subsidiary, net of cash acquired	-	(12,339)
Dividends from associates	-	398
Loans granted to related parties	-	(29,720)
Loans payment from related parties	-	21,055
Proceeds from sale of property, plant and equipment	233	545
Net cash used in investing activities	(9,948)	(51,577)
Cash flow from financial activities		
Bank loans proceeds	28,004	367,591
Bank loans payments	(55,903)	(423,883)
Dividends distribution	-	(3,400)
Principal elements of lease liabilities payments	(336)	(6,554)
Transaction costs	(118)	(973)
Leaseback proceeds	-	34,770
Principal elements of leaseback payments	(5,779)	(14,801)
Payments of long-term debt	(489)	(23,297)
Net cash provided by financial activities	(34,621)	(70,547)
Net (decrease) increase in cash during the period	(2,024)	13,670
Effect of movements in exchange rates on cash held	-	(2,197)
Cash and cash equivalents at beginning of period	35,376	23,903
Cash and cash equivalents at end of period	33,352	35,376

# Financial Statements 1Q 2025 - Preliminary Balance Sheet



	For the period ended	
	31.03.2025	31.12.2024
Assets		
Non-current assets		
Property, plant and equipment, net	699,819	697,000
Right of use asset	27,986	29,995
Investments in associated companies	18,710	18,165
Intangibles	10,907	11,338
Deferred income tax	4,398	3,581
Other accounts receivable	408	408
	762,228	760,487
Current assets		
Prepaid expenses	3,051	961
Current portion of biological assets	221,691	190,906
Inventories	31,830	80,292
Other accounts receivable	33,446	22,910
Trade accounts receivable	21,138	28,035
Cash and cash equivalents	33,352	35,376
	344,508	358,480
Total assets	1,106,736	1,118,967

	For the pe	For the period ended	
	31.03.2025	31.12.2024	
Equity and liabilities			
Capital and reserve attributable to			
shareholders of the Company			
Share capital	10,000	10,000	
Revaluation of assets	172,973	172,973	
Retained earnings	188,712	161,707	
	371,685	344,680	
Minority interests	- 998	- 996	
Total equity	370,687	343,684	
Non-current liabilities			
Long-term debt	317,265	317,446	
Lease liability	77,833	84,979	
Deferred income tax	123,039	121,748	
	518,137	524,173	
Current liabilities			
Accounts payable to related companies	36	31	
Current portion of long-term debt	3,641	8,377	
Current portion of lease liability	20,396	20,719	
Trade payables	108,908	107,319	
Other payables	44,373	46,887	
Bank loans	40,558	67,777	
	217,912	251,110	
Total liabilities	736,049	775,283	
Total equity and liabilities	1,106,736	1,118,967	







Búscanos como CamposolCares en:







Búscanos como Camposol en:



Para más información por favor conectarse a: www.camposol.com.pe

For more information please log into: www.camposol.com.pe